In murine arthritis, tofacitinib reduces levels of plasma IL-6 and CXCL10 (IFN-γ–induced protein 10), while in rheumatoid arthritis (RA), it lowered IL-6 in one clinical trial but decreased CXCL10 in another. This evidence concerns the gene IL6 and rheumatoid arthritis.